Peroxisome proliferator-activated receptor γ and retinoid X receptor transcription factors are released from activated human platelets and shed in microparticles

Thrombosis and Haemostasis

Volumn 99, Issue 1, 2008, Pages 86-95

  Ray, Denise M ^a   Spinelli, Sherry L ^a   Pollock, Stephen J ^a   Murant, Thomas I ^a   O'Brien, Jamie J ^a   Blumberg, Neil ^a   Francis, Charles W ^a   Taubman, Mark B ^a   Phipps, Richard P ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Microparticles; Peroxisome proliferator activated receptor (PPAR ); Platelets; Retinoic X receptor (RXR); Transcription factors

Indexed keywords

ADENOSINE DIPHOSPHATE; COLLAGEN; DNA; LATRUNCULIN A; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 1; RETINOID X RECEPTOR; ROSIGLITAZONE; THROMBIN; THROMBIN RECEPTOR ACTIVATING PEPTIDE 6; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; INTERNALIZATION; MALE; MONOCYTE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN SECRETION; THROMBOCYTE ACTIVATION; THROMBOCYTE FUNCTION; THROMBOCYTE METABOLISM; THROMBOCYTE RELEASE REACTION;

ADULT; BICYCLO COMPOUNDS, HETEROCYCLIC; BLOOD PLATELETS; CELL LINE, TUMOR; COLLAGEN; DIMERIZATION; DNA; FEMALE; HUMANS; MALE; MEGAKARYOCYTES; MIDDLE AGED; MONOCYTES; PEPTIDE FRAGMENTS; PLATELET ACTIVATION; PPAR GAMMA; PROTEIN BINDING; PROTEIN ISOFORMS; RETINOID X RECEPTOR ALPHA; RETINOID X RECEPTOR BETA; RETINOID X RECEPTORS; RNA, MESSENGER; THIAZOLIDINEDIONES; THIAZOLIDINES; THROMBIN; TIME FACTORS; TRANSPORT VESICLES;

EID: 38349166623     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH07-05-0328     Document Type: Article

References (47)

1. Daynes RA, Jones DC. Emerging roles of PPARs in inflammation and immunity. Nat Rev Immunol 2002; 2: 748-759.
2. Yanase T, Yashiro T, Takitani K, et al. Differential expression of PPAR γ1 and γ2 isoforms in human adipose tissue. Biochem Biophys Res Commun 1997; 233: 320-324.
3. Padilla J, Leung E, Phipps RP. Human B lymphocytes and B lymphomas express PPAR-γ and are killed by PPAR-γ agonists. Clin Immunol 2002; 103: 22-33.
4. Ricote M, Li AC, Willson TM, et al. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature 1998; 391: 79-82.
5. Fajas L, Auboeuf D, Raspe E, et al. The organization, promoter analysis, and expression of the human PPARγ gene. J Biol Chem 1997; 272: 18779-18789.
6. Kelly D, Campbell JI, King TF, et al. Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclear-cytoplasmic shuttling of PPAR-γ and RelA. Nat Immunol 2004; 5: 104-112.
7. Kliewer SA, Umesono K, Noonan DJ, et al. Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature 1992; 358: 771-774.
8. Lehmann JM, Moore LB, Smith-Oliver TA, et al. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPAR γ). J Biol Chem 1995; 270: 12953-12956.
9. 2 is a ligand for the adipocyte determination factor PPAR γ. Cell 1995; 83: 803-812.
10. Feldon SE, O'Loughlin C W, Ray DM, et al. Activated Human T Lymphocytes Express Cyclooxygenase-2 and Produce Proadipogenic Prostaglandins that Drive Human Orbital Fibroblast Differentiation to Adipocytes. Am J Pathol 2006; 169: 1183-1193.
11. McIntyre TM, Pontsler AV, Silva AR, et al. Identification of an intracellular receptor for lysophosphatidic acid (LPA): LPA is a transcellular PPARg agonist. Proc Natl Acad Sci U S A 2003; 100: 131-136.
12. Investigators TDT. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial. Lancet; prepublished online September 15, 2006, doi:10.1016[S0140-6736(06)69420-8
13. Akbiyik F, Ray DM, Gettings KF, et al. Human bone marrow megakaryocytes and platelets express PPARg, and PPARg agonists blunt platelet release of CD40 ligand and thromboxanes. Blood 2004; 104: 1361-1368.
14. Wagner DD, Burger PC. Platelets in inflammation and thrombosis. Arterioscler Thromb Vasc Biol 2003; 23: 2131-2137.
15. Lambert MP, Sachais BS, Kowalska MA. Chemokines and thrombogenicity. Thromb Haemost 2007; 97: 722-729.
16. von Hundelshausen P, Petersen F, Brandt E. Platelet-derived chemokines in vascular biology. Thromb Haemost 2007; 97: 704-713.
17. Henn V, Slupsky JR, Grafe M, et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998; 391: 591-594.
18. Tan KT, Lip GY. The potential role of platelet microparticles in atherosclerosis. Thromb Haemost 2005; 94: 488-492.
19. Blann AD, Tan KT, Tayebjee MH, et al. Soluble CD40L in peripheral artery disease. Relationship with disease severity, platelet markers and the effects of angioplasty. Thromb Haemost 2005; 93: 578-583.
20. Phipps RP. Atherosclerosis: the emerging role of inflammation and the CD40-CD40 ligand system. Proc Natl Acad Sci U S A 2000; 97: 6930-6932.
21. Jackson SP, Schoenwaelder SM. Antiplatelet therapy: in search of the 'magic bullet'. Nat Rev Drug Discov 2003; 2: 775-789.
22. Bode AF, Sandberg H, Dombrose FA, et al. Association of factor V activity with membranous vesicles released from human platelets: requirement for platelet stimulation. Thromb Res 1985; 39: 49-61.
23. Horstman LL, Jy W, Jimenez JJ, et al. New horizons in the analysis of circulating cell-derived microparticles. Keio J Med 2004; 53: 210-230.
24. Weyrich AS, Lindemann S, Zimmerman GA. The evolving role of platelets in inflammation. J Thromb Haemost 2003; 1: 1897-1905.
25. Koppler B, Cohen C, Schlondorff D, et al. Differential mechanisms of microparticle transfer to B cells and monocytes: anti-inflammatory properties of microparticles. Eur J Immunol 2006; 36: 648-660.
26. Sims PJ, Wiedmer T, Esmon CT, et al. Assembly of the platelet prothrombinase complex is linked to vesiculation of the platelet plasma membrane. Studies in Scott syndrome: an isolated defect in platelet procoagulant activity. J Biol Chem 1999; 264: 17049-17057.
27. Tans G, Rosing J, Thomassen MC, et al. Comparison of anticoagulant and procoagulant activities of stimulated platelets and platelet-derived microparticles. Blood 1991; 77: 2641-2648.
28. Nomura S, Tandon NN, Nakamura T, et al. High-shear-stress-induced activation of platelets and microparticles enhances expression of cell adhesion molecules in THP-1 and endothelial cells. Atherosclerosis 2001; 158: 277-287.
29. Diamant M, Nieuwland R, Pablo RF, et al. Elevated numbers of tissue-factor exposing microparticles correlate with components of the metabolic syndrome in uncomplicated type 2 diabetes mellitus. Circulation 2002; 106: 2442-2447.
30. Janowska-Wiexzorek AKJ, Marquez LA, Ratajczak J, et al. Microvesicles derived from activated platelets: an under-appreciated modulator of the metastatic potential of tumor cells. Blood 2003; 102: 57b #3998.
31. Ogura M, Morishima Y, Ohno R, et al. Establishment of a novel human megakaryoblastic leukemia cell line, MEG-01, with positive Philadelphia chromosome. Blood 1985; 66: 1384-1392.
32. Avanzi GC, Brizzi MF, Giannotti J, et al. M-07e human leukemic factor-dependent cell line provides a rapid and sensitive bioassay for the human cytokines GM-CSF and IL-3. J Cell Physiol 1990; 145: 458-464.
33. Ray DM, Bernstein SH, Phipps RP. Human multiple mycloma cells express peroxisome proliferator-activated receptor γ and undergo apoptosis upon exposure to PPARγ ligands. Clin Immunol 2004; 113: 203-213.
34. Kaiser PC, Korner M, Kappeler A, et al. Retinoid receptors in ovarian cancer: expression and prognosis. Ann Oncol 2005; 16: 1477-1487.
35. Heijnen HF, Schiel AE, Fijnheer R, et al. Activated platelets release two types of membrane vesicles: microvesicles by surface shedding and exosomes derived from exocytosis of multivesicular bodies and alpha-granules. Blood 1999; 94: 3791-3799.
36. Flaumenhaft R, Dilks JR, Rozenvayn N, et al. The actin cytoskeleton differentially regulates platelet alpha-granule and dense-granule secretion. Blood 2005; 105: 3879-3887.
37. Gnatenko DV, Dunn JJ, McCorkle SR, et al. Transcript profiling of human platelets using microarray and serial analysis of gene expression. Blood 2003; 101: 2285-2293.
38. Leesnitzer LM, Parks DJ, Bledsoe RK, et al. Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662. Biochemistry 2002; 41: 6640-6650.
39. von Knethen A, Soller M, Tzieply N, et al. PPAR-gammal attenuates cytosol to membrane translocation of PKCalpha to desensitize monocytes/ macrophages. J Cell Biol 2007; 176: 681-694.
40. Fox JE, Austin CD, Boyles JK, et al. Role of the membrane skeleton in preventing the shedding of pro-coagulant-rich microvesicles from the platelet plasma membrane. J Cell Biol 1990; 111: 483-493.
41. Johnson BA, Wilson EM, Li Y, et al. Ligand-induced stabilization of PPARgamma monitored by NMR spectroscopy: implications for nuclear receptor activation. J Mol Biol 2000; 298: 187-194.
42. Pascual G, Fong AL, Ogawa S, et al. A SUMOy-lation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-γ. Nature 2005; 437: 759-763.
43. Moraes LA, Swales KE, Wray JA, et al. Nongenomic signaling of the retinoid X receptor through binding and inhibiting Gq in human platelets. Blood 2007; 109: 3741-3744.
44. Scholz T, Temmler U, Krause S, et al. Transfer of tissue factor from platelets to monocytes: role of platelet-derived microvesicles and CD62P. Thromb Haemost 2002; 88: 1033-1038.
45. Janowska-Wieczorek A, Majka M, Kijowski J, et al. Platelet-derived microparticles bind to hematopoietic stem/progenitor cells and enhance their engraftment. Blood 2001; 98: 3143-3149.
46. Singh N, Webb R, Adams R, et al. The PPAR-gamma activator, Rosiglitazone, inhibits actin poly-merisation in monocytes: involvement of Akt and intra-cellular calcium. Biochem Biophys Res Commum 2005; 333: 455-462.
47. Sumita C, Maeda M, Fujio Y, et al. Pioglitazone induces plasma platelet activating factor-acetylhydrolase and inhibits platelet activating factor-mediated cytoskeletal reorganization in macrophage. Biochim Biophys Acta 2004; 1673: 115-121.